Galimedix Therapeutics-preview

Galimedix

Galimedix Therapeutics

Private

Kensington, MarylandHealthcare & Life Scienceshttps://galimedix.com/

Last Round

Strategic

Mar 29, 2023

Momentum Score

25 /100

Company Overview

Galimedix Therapeutics is a clinical-stage biotechnology company that develops small molecule drugs for neurodegenerative diseases such as dry age-related macular degeneration (AMD), glaucoma, and Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

amyloid beta inhibitorsmall molecule drugneurodegenerative disease therapyanti-amyloid therapyAlzheimer's disease treatmentdry AMD treatmentglaucoma treatmentclinical stage biotechophthalmology drugdrug developmentgeographic atrophy treatmentGA treatmenttopical eye dropsoral formulationdrug licensingneuroprotectionoligomer formation inhibitor

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Galimedix Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Galimedix Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Strategic	Mar 29, 2023
Seed	Jan 1, 2019

View all Funding Rounds

Key People

Founding team and executive leadership

Hermann Russ

Co-Founder And Chief Scientific Officer Of Galimedix Therapeutics Inc.

Founding Team

Phyllis Bellin

Chief Financial Officer

Executive Team

Galimedix Therapeutics Investors

Notable investors and investment history

Investor	Rounds
Théa Open Innovation	Strategic
Rimonci	Seed
InFocus Capital Partners	Seed

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

May 1, 2025
Monthly visitors increased 217% MoM.
Oct 29, 2024
Monthly visitors increased 30% MoM, from 543 to 708.

View all signals

Galimedix Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Galimedix Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Galimedix Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersKensington, Maryland

Employee Range12

Year Founded2018

Last FundingMar 29, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.